Connexin 43 is an independent predictor of patient outcome in breast cancer patients by Chasampalioti, Maria et al.
Vol.:(0123456789) 
Breast Cancer Research and Treatment 
https://doi.org/10.1007/s10549-018-5063-9
PRECLINICAL STUDY
Connexin 43 is an independent predictor of patient outcome in breast 
cancer patients
Maria Chasampalioti1 · Andrew R. Green2 · Ian O. Ellis2,3 · Emad A. Rakha2,3 · Andrew M. Jackson4 · Ian Spendlove1 · 
Judith M. Ramage1,5
Received: 5 November 2018 / Accepted: 16 November 2018 
© The Author(s) 2018
Abstract
Purpose Gap junctions are specialized membrane structures that form channels between adjacent cells allowing cell com-
munication. Gap junctions and specifically Connexin 43 (Cx43) are down-regulated in cancer; however, there are contrasting 
reports on how this effects breast cancer patient survival. This paper is the first large-scale tissue microarray analysis of Cx43 
expression in breast cancer patients with an associated clinical long-term follow-up.
Methods Using a validated TMA of 1118 primary breast cancers, coupled to a comprehensive database of clinicopathologi-
cal variables, the expression levels and subcellular localisation of Cx43 was assessed by immunohistochemistry. Its impact 
in terms of survival, distant metastasis-free survival, and clinicopathological variables was determined.
Results Patients whose tumors expressed high levels of Cx43 had significantly better survival (p < 0.001) than patients 
with low levels. High Cx43 expression within tumors was associated with an 18-month survival advantage. Loss of Cx43 
expression was associated with markers of poor prognosis, namely large tumor size, high grade, high proliferation status, 
high pleomorphism, high mitosis, poor Nottingham Prognostic Index (NPI), and triple negative tumors. Cx43 expression 
was independent of tumor size, grade, stage and ER-status in predicting poor survival on multivariate analysis (p = 0.004).
Conclusion Connexin 43 (Cx43) is an independent predictor of breast cancer survival and distant metastasis-free survival. 
High expression of Cx43 was seen in only 13% of tumors, suggesting that drugs to increase Cx43 expression may result in 
prolonged patients survival.
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Introduction
Connexin 43 (Cx43) has dual functions due to its involve-
ment in cell-to-cell communication through gap junctions 
and in maintenance of homeostasis. Gap junctions are spe-
cialized membrane structures that permit the formation of 
channels between adjacent cells. Two hemi-channels (made 
up of 6 connexins) pair to form an intracellular gap junction 
channel allowing the passage of second messengers, ions 
and other small molecules (< 1000 Da), in a process known 
as gap junctional intracellular communication (GJIC) [1]. 
The carboxyl-terminus (C-terminus) regulatory domain of 
Cx43 is located in the cytoplasm. This is the primary site of 
its protein:protein interactions and phosphorylation and has 
been demonstrated to have a role in its intracellular functions 
such as proliferation, apoptosis, and migration [2].
There have been reports that expression levels of Cx43 
are altered in breast cancer, however, there is controversy 
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1054 9-018-5063-9) contains 
supplementary material, which is available to authorized users.
 * Judith M. Ramage 
 Judith.ramage@nottingham.ac.uk
1 Cancer Immunology Group, Division of Cancer and Stem 
Cells, School of Medicine, University of Nottingham, 
Nottingham, UK
2 Division of Cancer and Stem Cells, Nottingham Breast 
Cancer Research Centre, School of Medicine, University 
of Nottingham, Nottingham, UK
3 Department of Pathology, Nottingham University Hospitals 
NHS Trust, Nottingham City Hospital, Nottingham, UK
4 Host-tumour interactions Group, Division of Cancer 
and Stem cells, School of Medicine, University 
of Nottingham, Nottingham, UK
5 Academic Unit of Clinical Oncology, University 
of Nottingham, Nottingham City Hospital, 
Nottingham NG5 1PB, UK
 Breast Cancer Research and Treatment
1 3
over its role in patient survival [3]. In a small study of 
32 patient samples, Cx43 was shown to correlate with 
poor survival in breast cancer [4]. In contrast, a study of 
invasive breast carcinoma by Conklin et al. showed no 
correlation of Cx43 expression with patient outcome [5]. 
More recently a meta-analysis of transcriptome data has 
shown an association between loss of Cx43 expression 
and poor prognosis [6]. But again, in apparent contrast, 
Stolevoc et al. found that RNA expression was associated 
with increased patient death and recurrence [7] in primary 
breast cancer.
High levels of expression of Cx43 on metastatic cells 
in the lymph node [8] and brain [7] have led to the sug-
gestion that Cx43 plays a role in metastasis. There is con-
troversy here as well, as in apparent contrast, where Cx43 
expression is down-regulated [9–11], in animal models an 
increase in metastasis is associated with a loss of Cx43. 
This is reinforced by experiments in Cx43 knockout mice 
[12].
As Cx43 has an underlying importance in controlling a 
range of cellular functions, it is perhaps not surprising that it 
is dysregulated in cancer. Cx43 is expressed in normal breast 
tissue [13], where it localized to the plasma membrane [14] 
however, in tumors there is a loss or mislocalisation of Cx43 
from the plasma membrane to cytoplasm [8]. This has led to 
the debate of whether the tumor suppressor function of Cx43 
is gap junction dependent or independent [9, 11]. There is 
therefore a requirement to further clarify the relevance of 
Cx43 localisation to survival.
We hypothesized that downregulation of Cx43 in tumors 
would lead to increased metastasis and poor survival in 
breast cancer patients. This paper is a large-scale tissue 
microarray analysis of Cx43 expression in breast cancer 
patients with an associated long-term follow-up. The expres-
sion of Cx43 in both the membrane and the cytoplasm were 
investigated due to previous reports of the importance of 
location. We demonstrate that Cx43 expression in either the 
membrane or cytoplasm is not only an independent predic-
tor of survival, it is also an independent predictor of distant 
metastasis-free survival in breast cancer.
Materials and methods
Ethical approval was granted by the Nottingham Research 
Ethics Committee (Nottingham Hospital Trust numbers 
Q1020402 and GS020402, REC202313). The samples used 
in this study have been described previous publications [15]. 
In an attempt to overcome some of the reporting deficiencies 
inherent in prognostic tumor marker studies, we followed the 
Reporting recommendations for tumor MARKer prognostic 
studies (REMARK) [16].
Study patients
This retrospective study was based on a series of 1118 
patients with primary invasive breast carcinomas who were 
diagnosed from 1987 to 1998 and entered onto the Notting-
ham Tenovus Primary Breast Carcinoma series. All patho-
logical characteristics were recorded at time of presentation 
including histologic tumor grade, histologic tumor type, 
tumor size, Nottingham prognostic index (NPI), vascular 
invasion, and protein expression. All patients had standard 
surgical treatment of mastectomy or local excision with 
radiotherapy. Breast cancer-specific survival and distant-free 
metastasis was measured in years from the date of the pri-
mary surgical treatment to the time of death of breast cancer.
Tissue microarrays and immunohistochemistry
At the time of resection, all tumors were managed in a 
standardized fashion, with immediate incision and fixa-
tion in neutral-buffered formalin to minimize any diffus-
ing problems, followed by processing through to embed-
ding in paraffin wax. Breast cancer tissue microarrays were 
prepared as previously described [15]. In brief, tissue cores 
with a diameter of 0.6 mm were punched from the repre-
sentative tumor regions of each donor block. Cores were 
precisely arrayed into new recipient paraffin block using a 
tissue microarrayer (Beecher Instruments). Immunohisto-
chemistry of 0.4 µm thick sections was performed utilizing 
the Novolink polymer detection system (Leica Biosystems, 
UK). Briefly tissue slides were deparaffinised with xylene 
and rehydrated through three changes of alcohol. Citrate 
buffer was used for antigen retrieval (20 min in microwave). 
To all slides 100 µl of Peroxidase Block (Novolink Kit) was 
added for 5 min, followed by two TBS washes and 100 µl 
of protein block for 5 min. After a further two TBS washes 
100 µl of anti-Cx43 antibody (Invitrogen™ Thermo-Fischer 
Scientific previously optimized at 12.5 µg/ml) was applied 
and slides were incubated for 1 h. Slides were washed twice 
with TBS and then incubated for 30 min with 100 µl Rab-
bit anti mouse IgG (Novolink kit). Then washed twice with 
TBS and incubated for 30 min with 100 µl of Novolink Poly-
mer of anti-rabbit Poly-HRP-IgG. Finally the sections were 
washed twice with TBS and 100 µl of DAB working solution 
(1:20 DAB chromogen in DAB substrate buffer (Novolink 
Kit)) was added for 5 min. After washing the slides twice 
with TBS they were counterstained with 100 µl of Novolink 
haematoxylin for 6 min dehydrated and a coverslip applied. 
Negative (omission of the primary antibody) and positive 
controls (anti-β-2 microglobulin) were included.
Breast Cancer Research and Treatment 
1 3
Evaluation of immunohistochemistry staining
Assessment of staining was based on semi quantitative 
approach using light microscopy. Cytoplasmic and mem-
branous expression of Cx43 was scored separately in each 
core. Membrane expression was scored as follows in terms 
of intensity as 0, 1, 2, or 3 for negative, weak, moderate 
and strong respectively. For the cytoplasmic scoring where 
percentage of tumor staining could readily be determined 
H-score were used to determine the cytoplasmic staining 
with both the intensity and percentage of staining assessed. 
Staining intensity was scored as 0, 1, 2, or 3 for negative, 
weak, moderate and strong respectively and multiplied by 
percentage staining (range 0–300).
Statistical analysis
The X-tile bioinformatics software version 3.4.7 was used 
for determination of the optimal cut-off points for Cx43 
expression based on prediction of breast cancer-specific sur-
vival. The Statistical analysis was performed using the SPSS 
21.0 statistical software (SPSS, USA). Univariate and mul-
tivariate analyses were performed by chi-squared, log rank, 
and Cox regression analysis, respectively. Survival curves 
were analyzed by Kaplan–Meier curves. A p-value < 0.01 
was considered significant.
Results
Low expression of Cx43 in primary breast cancer
A tissue microarray (TMA) series of 1980 breast patients 
was immunoprobed for Cx43 expression. From the origi-
nal series 1118 (48%) had sufficient cores for scoring to be 
performed, the remaining cores were lost during antigen 
retrieval or did not have sufficient tumor cells present. Sup-
plementary table 1 demonstrates that the clinicopathological 
variables of the cohort did not vary greatly from the origi-
nal whole dataset. Intensity of staining was categorized as 
high, moderate, weak (Fig. 1b–d), or negative (Fig. 1a) in 
the cytoplasm and the membrane (Fig. 1e–g).
For cytoplasmic expression where the percentage staining 
of the tumor could be readily determined, the intensity (Fig. 1 
c–e) was multiplied by percentage staining to give H-scores. 
Cytoplasmic Cx43 expression was dichotomised as low 
(H-score range 0–180) and high (H-score range 181–300). For 
membranous Cx43 expression, where percentage staining was 
not readily determined, the high, moderate, weak, and negative 
cores were further divided into 2 categories: low [combining 
negative and weak (Fig. 1a, g)] and high [combining moderate 
and high (Fig. 1e, f)] expression. The majority of tumors had 
low Cx43 membranous expression [87% cases; mean score 
of 0.92 (range 0–3)] and low expression (73% of cores) in the 
cytoplasm (mean H-score of 106).
Low Cx43 expression associated with known 
clinicopathological markers of poor prognosis
Low levels of Cx43 expression in either the membrane or the 
cytoplasm were significantly associated with known markers 
of poor prognosis: tumor size (membrane p = 0.02; cyto-
plasm p = 0.001), higher grade (p < 0.0001), high nuclear 
and cellular pleomorphism (membrane p = 0.002; cytoplasm 
p < 0.0001), high mitosis frequency (p < 0.0001), and poor 
NPI (p < 0.0001) (Table 1). In terms of tumor biology, there 
was an association between low Cx43 and ER, PgR, and 
HER2 negativity and triple negative tumors (all p < 0.0001). 
Low levels of expression were associated with high prolif-
eration (ki67 + p < 0.0001) levels. Low levels of membrane 
expression were also significantly associated with pre-men-
opausal and younger patients (Table 1).
Low Cx43 expression is associated with poor patient 
outcome
Low expression of both membranous and cytoplasmic Cx43 
showed a statistically significant association with breast 
cancer-specific survival (p < 0.0001; Fig. 2a, b; Table 2) 
with survival at 206 months compared to 244 months for 
low membrane expression and 200 months compared to 243 
months for low cytoplasmic expression. However, patients 
whose tumors had high Cx43 expression in both the cyto-
plasm and the membrane had a better survival outcome than 
those that were only positive in the cytoplasm (252 months 
compared to 235 months, p < 0.0001; Fig. 2c). No expression 
of Cx43 was the worst prognosis (200 months). There were 
limited numbers of only high Cx43 membrane expression.
Low Cx43 expression associated with shortened 
distant metastasis‑free survival
Moreover, low Cx43 membranous expression predicted 
shortened distant metastasis-free survival giving a 14 month 
disadvantage than high expression (166 months compared 
with 188 months). Similarly, low Cx43 cytoplasmic expres-
sion gave 15-month survival disadvantage over high expres-
sion (162 months compared to 186 months; p < 0.0001) 
(Fig. 2d, e).
Cx43 expression is an independent predictor 
of patient survival and distant metastasis‑free 
survival
Multivariate Cox regression analysis demonstrated that 
Cx43 expression, either membranous or cytoplasmic, was 
 Breast Cancer Research and Treatment
1 3
Fig. 1  Photomicrographs of 
breast TMA scores immuno-
histochemically stained for 
Cx43 (a–g). The level of Cx43 
expression ranged from b high, 
c moderate, d weak to (a) nega-
tive for cytoplasm and from e 
high, f moderate, g weak for 
membrane
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Table 1  Association between the expression of cytoplasmic and membrane Connexin43 (Cx43) and Clinicopathologic features in primary breast 
cancer
Clinicopathological variables Cytoplasmic expression Membrane Expression
Low (%) High (%) p-value Low (%) High (%) p-value
Menopause
 Pre 326 (75) 112 (25) 371 (84) 67 (15)
 Pos 491 (73) 177 (26) 0.732 595 (89) 73 (10) 0.033
Age diagnosis
 ≤ 50 295 (74) 103 (26) 336 (84) 62 (16)
 > 50 525 (73) 192 (27) 0.744 635 (89) 82 (11) 0.048
Tumor size
 ≤ 2.0 cm 368 (69) 166 (31) 452 (85) 82 (15)
 > 2.0 cm 452 (78) 129 (22) 0.001 519 (89) 62 (11) 0.02
Grade
 1 97 (55) 80 (45) 135 (76) 42 (24)
 2 246 (65) 130 (35) 316 (84) 60 (16)
 3 477 (85) 85 (15) < 0.0001 519 (92) 145 (13) < 0.0001
Tubule formation
 1 (majority of tumor,< 75%) 28 (48) 30 (52) 37 (64) 21 (62)
 2 (moderate degree, 10–75%) 241 (65) 131 (35) 304 (82) 68 (18)
 3 (little or none, < 1% none, < 10%) 523 (80) 290 (27) < 0.0001 599 (92) 53 (8) < 0.001
Pleomorphism
 1 (small, regular uniform cells) 15 (68) 7 (32) 16 (73) 6 (27)
 2 (moderate increase in size and 
variablility)
253 (62) 156 (38) 341 (83) 68 (17)
 3 (marked variation) 524 (80) 127 (20) < 0.0001 583 (90) 68 (10) 0.002
Mitosis
 1 208 (60) 141 (40) 284 (81) 65 (15)
 2 151 (67) 75 (33) 185 (82) 41 (18)
 3 433 (85) 74 (15) < 0.0001 940 (87) 142 (13) < 0.0001
Tumor type
 Ductal 690 (73) 251 (27) 818 (87) 123 (13)
 Lobular 71 (75) 24 (25) 88 (93) 7 (7)
 Medullary-like 22 (96) 1 (4) 23 (100) 0 (0)
 Miscellaneous 4 (80) 1 (20) 4 (80) 1 (20)
 Special type 33 (65) 18 (35) 0.091 38 (74) 13 (25) 0.009
Vascular invasion
 Absent 521 (72) 201 (28) 626 (87) 96 (13)
 Present 295 (76) 93 (24) 0.164 341 (88) 47 (12) 0.575
Ki67
 Low 180 (63) 105 (37) 241 (85) 44 (15)
 High 510 (79) 138 (21) < 0.0001 578 (89) 70 (11)
Nodal stage
 1 469 (71) 190 (29) 570 (86) 89 (13)
 2 275 (75) 91 (25) 318 (87) 48 (13)
 3 76 (84) 14 (15) 0.019 82 (91) 8 (9) 0.473
NPI
 Good 184 (57) 140 (43) 261 (81) 63 (19)
 Moderate 473 (79) 124 (21) 532 (89) 65 (11)
 Poor 163 (84) 31 (16) < 0.0001 178 (92) 16 (8) < 0.0001
ER-status
 Negative 273 (96) 12 (4) 282 (99) 3 (1)
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independent of tumor size, grade, stage, and ER-status in 
predicting breast cancer-specific (membrane p = 0.003; cyto-
plasmic p = 0.004) and metastasis-free survival (membrane 
p = 0.003; cytoplasmic p = 0.005) (Table 3).
Discussion
Previous studies have highlighted that Cx43 expression is 
dysregulated in breast cancer, but there is no consensus on 
its role in patient survival and prediction of metastasis. In 
this study of over 1000 breast cancer patients with 30 years 
follow-up, low Cx43 expression was associated with poor 
patient prognosis and outcome. Indeed, low expression cor-
related with a wide range of established clinicopathological 
markers of poor prognosis such as larger tumor size, higher 
grade, poor NPI, and triple negative status. Therefore, the 
more aggressive tumors had low/ no expression of Cx43. 
Low expression of Cx43 was an independent predictor of 
patient survival. Importantly, to the best of our knowledge, 
this is also the first report of Cx43 as an independent predic-
tor of distant metastasis-free survival.
In contrast to previous studies that used significantly 
lower numbers of patient samples, this study analyzed over 
1000 primary tissue samples and we were therefore able to 
firmly establish that Cx43 is an independent predictor of sur-
vival. This is in agreement with a recent meta-analysis study 
of RNA levels in breast cancer, which also demonstrated, 
that Cx43 was an independent predictor of poor survival [6]. 
However, these results are in contrast to a paper by Conklin 
et al. using invasive breast carcinoma [17], which showed 
no correlation of Cx43 protein expression with patient 
outcome. This paper primarily observed Cx43 expression 
in the cytoplasm and did not observe membrane expression. 
In our analysis expression of Cx43 in both membrane and 
cytoplasm was associated with the best patient survival. It 
may have been that the Conkilin et al. analysis had a larger 
portion of higher grade patients in their samples but as there 
are no clinical characteristics given in their paper we are 
unable to compare.
Cx43 is hormone responsive [18, 19], and this may 
explain the positive correlation of Cx43 expression with 
both ER- and PgR-status. These findings are in agreement 
with Conkil et al. who showed that Cx43 correlated with ER-
status [17]. Cx43 expression was inversely correlated with 
Ki67, consistent with other data [17] and this would suggest 
that loss of Cx43 resulted in increased proliferation of cells.
There has been debate over the expression of Cx43 at 
different stages of cancer [20]. This study clarifies the corre-
lation of aggressive tumors/triple negative tumors with low 
Cx43 expression. Moreover, our analysis is the first to report 
that Cx43 is an independent predictor of metastasis-free sur-
vival and thereby supports the hypothesis of Mao et al. that 
gap junctions serve as an “intracellular glue” to suppress 
metastasis [21]. An elegant animal model study by Saunders 
et al. showed that transfection of the metastatic suppressor 
gene (BRMS1) into a human breast cancer metastatic cell 
Bold indicates significant p-value (< 0.05). Clinicopathological variables
NPI Nottingham prognostic index
Table 1  (continued)
Clinicopathological variables Cytoplasmic expression Membrane Expression
Low (%) High (%) p-value Low (%) High (%) p-value
 Positive 536 (65) 283 (35) < 0.0001 680 (83) 139 (17) < 0.0001
PgR-status
 Negative 407 (91) 39 (9) 429 (96) 17 (4)
 Positive 380 (61) 246 (39) < 0.0001 506 (81) 120 (19) < 0.0001
HER2 status
 Negative 654 (70) 276 (30) 796 (86) 134 (14)
 Positive 126 (93) 9 (7) < 0.0001 132 (98) 3 (2) < 0.0001
Triple negative
 Non-triple 600 (68) 284 (32) 745 (84) 139 (16)
 Triple negative 188 (94) 11 (5) < 0.0001 196 (98) 3 (1) < 0.0001
Basal phenotype
 Negative 569 (70) 241 (30) 690 (85) 120 (15)
 Positive 235 (84) 46 (16) < 0.0001 262 (93) 19 (7) < 0.0001
Fig. 2  Low Cx43 expression associated with poor breast cancer 
patient survival. Kaplan–Meier curves of membrane CX43 expres-
sion association with survival (a) cytoplasm Cx43 staining associa-
tion with survival (b), Cx43 membrane  (M) and Cx43 cytoplasmic 
(C)  co-expression association with survival (c) membrane Cx43 
expression and distant metastasis-free survival (d) and Cytoplasmic 
Cx43 expression and distant metastasis-free survival (e)
▸
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line restored intracellular gap junctional communication 
and correlated with improved survival due to less metasta-
sis [22]; thereby, highlighting the requirement for Cx43 to 
prevent metastasis. This is also consistent with mouse mod-
els where a high metastatic potential correlated with loss 
of IJC [9–11] and also in Cx43 knockout mice [12] which 
had higher metastasis in tumor models than wild-type mice 
from transplantable tumors. Therefore, indicating that higher 
expression of Cx43 is important in preventing metastasis.
There is some apparent controversy in the literature 
regarding the role of Cx43 in metastasis due to the reports 
of high Cx43 in metastatic tissue [8] of cancer patients. 
However, the literature would be consistent with downreg-
ulation of Cx43 being required for tumors to metastasise 
and that once they have metastasised they upregulate Cx43 
as postulated by Stoletov et al. [7]. Indeed Elzarrad et al. 
[23] state that some stages of tumorigenesis and metas-
tasis (uncontrolled cell division and cellular detachment) 
Table 2  Mean survival time and mean distant metastasis-free survival in relation to Cx43 expression in the membrane or the cytoplasm
Expression Cx43 membrane expression Cx43 cytoplasmic expression
Estimate 
(months)
95% confidence interval p value Estimate 
(months)
95% confidence interval p value
Lower bound Upper bound Lower bound Upper bound
Mean survival time
 High 244 227 262 < 0.0001 243 231 256 < 0.0001
 Low 206 198 214 200 192 209
 Overall 212 204 219 212 204 219
Distant metastasis-
free survival (mean)
 High 188 171 205 < 0.0001 186 178 199 < 0.0001
 Low 166 159 173 162 154 169
 Overall 169 163 175 169 163 175
Table 3  Multivariate analysis of Cx43 expression compared with tumor stage, grade, size, and ER-status for breast cancer specifc survival and 
distant metastasis free survival
Bold indicates P value for Cx43 expression as an independent predictor
Breast cancer specific survival
Expression Membrane expression Cytoplasmic expression
Hazard ratio 95% confidence interval Hazard ratio 95% confidence interval
Lower bound Upper bound P value Lower bound Upper bound P value
 Tumor stage 1.866 1.605 2.169 0.0001 1.854 1.595 2.155 0.0001
 Tumor grade 1.639 1.367 1.964 0.0001 1.597 1.331 1.918 0.0001
 Tumor size 1.339 1.076 1.666 0.009 1.330 1.069 1.654 0.011
 ER-status 1.214 0.949 1.554 0.122 1.242 0.968 1.592 0.088
 Cx43 expression 0.546 0.546 0.364 0.003 0.0664 0.664 0.502 0.004
Distant metastasis free survival
Expression Membrane expression Cytoplasmic expression
Hazard ratio 95% confidence interval Hazard ratio 95% confidence interval
Lower bound Upper bound P value Lower bound Upper bound P value
 Tumor stage 1.943 1.682 2.253 0.0001 1.927 1.668 2.234 0.0001
 Tumor grade 1.508 1.270 1.777 0.0001 1.469 1.235 1.734 0.0001
 Tumor size 1.345 1.092 1.669 0.009 1.341 1.089 1.664 0.007
 ER-status 1.231 0.958 1.570 0.122 1.260 1.254 0.978 0.069
 Cx43 expression 0.638 0.449 0.909 0.003 0.684 0.528 0.528 0.005
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require loss of gap junctions, while other stages (intravasa-
tion, endothelial attachment, and vascularization) require 
increased cell–cell contact. They hypothesize that this is a 
multi-stage scheme where Cx43 is involved centrally as a 
cell adhesion molecule mediating metastatic tumor attach-
ment to pulmonary endothelium. Furthermore, the Knock-
down of Cx43 has also been associated with activation of 
the Wnt/β-catenin signaling pathway, which is known to 
have a central role in cancer biology [24]. Indeed, blocking 
of the Wnt/β signaling suppresses breast cancer metasta-
sis. It is tempting to speculate that downregulation of Cx43 
results in increased Wnt/β signaling leading to increase 
metastasis.
The membrane localization of Cx43 expression has been 
associated with gap junctional communication between 
cells, whereas the cytoplasmic localization has been associ-
ated with cell homoeostasis (such as controlling cell prolif-
eration and apoptosis). Our study analyzed the expression 
of both membranous and cytoplasmic Cx43. The majority 
of tumors had low Cx43 expression (87%) in the membrane 
suggesting that the majority of tumors had lost expression 
from the membrane. Previous reports have shown a mislo-
calisation of expression of Cx43 from the plasma membrane 
to the cytoplasm in breast cancer [8]. We demonstrated that 
although Cx43 was detected in the cytoplasm this was at 
low levels in the majority of the tumors (73%). It has been 
hypothesized that cytoplasmic localization of Cx43 points 
to decreased GJIC. In human breast carcinomas tumor cell 
lines [3] the localization of Cx43 to the cytoplasm was not 
associated with gap junctional communication [20]. As 
Cx43 is not normally expressed in the cytoplasm our work 
is consistent with the hypothesis that Cx43 is mislocalised 
to the cytoplasm in breast cancer. In this study high expres-
sion of Cx43 in both the membrane and the cytoplasm, gave 
better survival that membrane only, which was better than 
no expression. Membrane only gave the worst prognosis, 
however we believe this was due to insufficient samples in 
this category. Therefore, this may suggest that as the tumor 
progresses it first dysregulates Cx43 to the cytoplasm and 
then loses Cx43 expression in the membrane before losing 
it completely.
In conclusion, Cx43 expression in breast cancer is a 
prognostic marker of survival and distant metastasis-free 
survival. Low levels of Cx43 give shorter patient survival; 
therefore, therapies to enhance its expression could lead to 
improvement in breast cancer patients survival. This has 
been demonstrated in animal models where retroviral deliv-
ery of Cx43 to tumors has been shown to increase survival 
[25]. Moreover, the drugs Geinstein and quercetin have been 
shown to increase Cx43 and suppress the growth of human 
breast cancer cell lines [17]. It would warrant future work to 
investigate Cx43 as a drugable target in breast cancer.
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